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Abstract
Objectives Our objective was to generate a value set for the SF-6Dv2 using time trade-off (TTO) and a discrete-choice 
experiment with a duration dimension  (DCETTO) in China.
Methods A large representative sample of the Chinese general population was recruited from eight provinces/municipalities 
in China, stratified by age, sex, education level, and proportion of urban/rural residence. Respondents completed eight TTO 
tasks and ten  DCETTO tasks during face-to-face interviews. Ordinary least squares (OLS), random-effects, fixed-effects, and 
Tobit models were used for TTO data, and conditional logit and mixed logit models were used for  DCETTO. The monotonicity 
of model coefficients and the consistency of the predicted values according to intraclass correlation coefficient (ICC), mean 
absolute difference (MAD), and mean squared difference (MSD) were compared between the two approaches.
Results In total, 3320 respondents (50.3% male; range 18–90 years) were recruited. The random-effects model and the con-
ditional logit model were preferred for the TTO and  DCETTO, respectively. The TTO values ranged from − 0.277 to 1, with 
927 (4.94%) states considered as worse than dead (WTD). The corresponding range for  DCETTO was − 0.535 to 1, with a 
higher WTD of 8.50%.  DCETTO presented minor non monotonicity with the coefficients in two dimensions. Values from the 
two approaches were highly consistent (ICC 0.9804, MAD 0.0588, MSD 0.0055), albeit those with  DCETTO were slightly 
lower than those with TTO. The value set generated by TTO was preferred given the better monotonicity and the statistical 
significance of coefficients.
Conclusions The Chinese value set for the SF-6Dv2 was established based on the TTO approach, but the  DCETTO also 
performed well. Minor issues of non monotonicity did present for  DCETTO.
Key Points for Decision Makers 
The Chinese value set for the SF-6Dv2 was established 
using a time trade-off (TTO) approach, which will facili-
tate the calculation of quality-adjusted life-years.
A direct comparison between the TTO and discrete-
choice experiment with a duration dimension  (DCETTO) 
approaches indicated a good performance for both; 
however, minor issues of non-monotonicity existed in 
 DCETTO estimates.
A systematic difference was found between value sets 
developed using the TTO and  DCETTO approaches.
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1 Introduction
Economic evaluations of healthcare interventions are 
becoming integral to the reimbursement decision-making 
process in many countries, including China [1, 2]. Cost-
utility analysis is a form of economic evaluation that quan-
tifies health outcomes on a standardized metric, typically the 
quality-adjusted life-year (QALY), a single value produced 
by multiplying a quality adjustment weight (or health utility) 
by life duration [2–4]. The health utility, which lies on a 0–1 
death–full health QALY scale, is calculated by a value set for 
a range of possible health states described by the health state 
classification system of generic preference-based measures. 
Examples of the most used measures include the EuroQol 
5-Dimensions (EQ-5D) and the Short-Form Six-Dimension 
(SF-6D) [2, 5, 6], both of which are recommended for use in 
Chinese guidelines for pharmacoeconomic evaluations [7].
The SF-6D is derived from the Short-Form 36 (SF-36) 
health survey, which is one of the most widely-used health-
related quality-of-life measures worldwide, including in 
China [2, 6, 8, 9]. The original health state classification 
system of the SF-6D comprises six dimensions with four to 
six levels in each, including physical functioning (PF), role 
limitation (RL), social functioning (SF), pain (PN), mental 
health (MH), and vitality (VT). Recently, a second version 
of the SF-6D, SF-6Dv2, was developed, which revisited the 
items selected from the SF-36 and modified the ambiguity 
between dimension levels and inconsistency of wording in 
the original version [8, 10]. The SF-6Dv2 has the same six 
dimensions as the SF-6Dv1, with five to six levels in each 
dimension, yielding up to 18,750 health states [2, 8, 10]. 
More details on the development of the SF-6Dv2 and com-
parisons with the SF-6Dv1 can be found elsewhere [8, 10]. 
The Simplified Chinese version of the SF-6Dv2 was devel-
oped after translation and cross-cultural adaption, and pre-
liminary psychometric testing was also conducted among the 
Chinese general population [11]. A country-specific value 
set for the SF-6Dv2 is currently available in the UK [12].
Health state utility values are commonly elicited using 
time trade-off (TTO) and standard gamble (SG) approaches 
[2, 13, 14]. Although TTO is generally regarded as simpler 
than SG, it is still considered too cognitively demanding for 
certain populations because of its iterative process, which 
may further result in response inconsistencies and subse-
quent data exclusions [2, 14–16]. A choice-based approach, 
the discrete-choice experiment (DCE), which some studies 
have argued may be simpler than the iterative process of 
TTO tasks, has recently gained popularity [16–19]. DCE 
tasks present two or more alternative health states, and 
respondents indicate their preference for one state over the 
other. However, a key problem in using DCEs has been how 
to anchor the values estimated by logit models, i.e., latent 
utilities, onto the QALY scale [20–23]. The DCE with a 
duration dimension  (DCETTO) approach, in which an addi-
tional dimension of life duration is presented with the health 
state, provides a valid alternative requiring no separate task 
or data manipulation for anchoring [19, 24–30].
Until now, no Chinese value set for the SF-6Dv2 has 
been available for the calculation of QALYs. A pilot study 
in 2018, based on a representative sample of the general 
population in Tianjin, China, was conducted to compare the 
acceptability, consistency, and accuracy of the TTO, DCE, 
and  DCETTO approaches in utility elicitation by using the 
SF 6Dv2 [31]. DCE and  DCETTO were found to be feasible in 
the establishment of value sets, but they were not considered 
easier to understand or answer than TTO, which is consistent 
with a previous study [19]. In the pilot study,  DCETTO had 
the highest completion rates and shortest completion time 
but showed a slight non-monotonicity on model coefficients 
[31], which has also been reported in other studies [12, 24, 
28–30]. Therefore, this study aimed to generate a Chinese 
value set for SF-6Dv2 and to compare TTO and  DCETTO 
approaches in a large representative sample of the general 
population in China.
2  Methods
Face-to-face interviews were conducted among a large rep-
resentative sample of the general population of China to col-
lect TTO and  DCETTO responses, which were then modeled 
to estimate utility values for all health states in the SF-6Dv2.
2.1  Elicitation Tasks Design
Both TTO and  DCETTO elicitation tasks were employed 
in this study. The composite TTO approach, which was 
developed by the EuroQol group [32, 33], was used in the 
TTO task (hereafter TTO) (Fig. 1a in the electronic sup-
plementary material [ESM]), where “better than dead” and 
“worse than dead” (WTD) states were valued by conven-
tional TTO and lead-time TTO, respectively. A detailed 
description of the composite TTO approach can be found 
elsewhere [31–33]. The health states ‘‘being in a wheel-
chair’’ and “being in a health state worse than dead” were 
used as warm-up questions to make sure respondents under-
stood the concept of TTO before proceeding to the formal 
tasks. In the  DCETTO task (Fig. 1b in the ESM), respondents 
were presented with a pair of health states described by the 
SF-6Dv2, with a further dimension representing the number 
of years living in that health state followed by death. Four 
levels of life-years were chosen: 1, 4, 7, and 10 years [12]. 
The longest duration was set to 10 years to be commensurate 
with the standard timeframe of the TTO task. Two stepwise 
warm-up questions were used in the  DCETTO tasks. The 
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first warm-up question consisted of a pair of health states 
described by three dimensions, the first two of which were 
randomly chosen from SF-6Dv2 dimensions, and the third 
dimension represented the life duration. In the second warm-
up question, two extra dimensions were further randomly 
chosen from the remaining SF-6Dv2 dimensions and added 
to describe the health states (i.e., five dimensions in total).
2.2  Health State Selection
The SF-6Dv2 defines a total of 18,750 health states, with 
more than 175 million potential pairwise combinations gen-
erated in the full factorial design. The number of possible 
combinations is even larger if the life duration dimension 
is added. A trade-off between the number of health states 
directly valued and the cognitive burden on respondents 
was considered following previous studies [31, 34, 35]. For 
TTO tasks, 295 health states described by the SF-6Dv2 were 
selected, including the six mildest imperfect health states 
(211111, 121111, 112111, 111211, 111121, 111112), the 
worst state (555655), and 288 other states generated based 
on near orthogonal arrays using  SAS® Studio. The mildest 
health states were deliberately included because it allowed 
direct observations to distinguish the mildest impairments 
from full health. The 288 states were first distributed over 48 
blocks, the state 555655 (included in all 48 blocks), and the 
six mildest states (each randomly included in eight blocks) 
were then added in the blocks. Each respondent was ran-
domly assigned a block (i.e., eight TTO tasks) for valuation.
For  DCETTO tasks, 300 pairs of health states (split into 30 
blocks) were generated using the balanced overlap method. 
Both main effects and two-way interactions between the lev-
els of each dimension and life-years were considered in the 
experimental design. Statistical efficiency was maximized 
with regard to the D-efficiency using Lighthouse Studio 
9.6.0 (Sawtooth Software, Inc.) [36–38]. Each respondent 
was randomly assigned a block (i.e., ten  DCETTO tasks) for 
valuation; the task order and the left–right position of health 
states within each task were all randomized.
2.3  Respondents
For each pair of  DCETTO tasks, 100 observations are 
expected to result in robust model estimation [12]. Accord-
ingly, the total target sample size was set at 3000. Respond-
ents were recruited from eight cities, including Wuhan (cen-
tral), Tianjin (north), Nanjing (east), Guangzhou (south), 
Lanzhou (northwest), Harbin (northeast), Chengdu, and Gui-
yang (southwest), as well as their surrounding rural areas, to 
achieve sufficient geographical spread and varied economic 
development levels in China (Fig. 2a in the ESM) [39, 40].
A stratified sampling method was used, in which four 
quotas were set for age, sex, education level, and proportion 
of urban/rural residence, to ensure these distributions of the 
sample resembled those of the Chinese general population 
[39, 40]. In each of the eight cities chosen in this study, 
seven to ten districts (for urban areas) and villages (for rural 
areas) were selected, and 40–60 respondents were then 
recruited in each district/village. Recruitment was conducted 
in publicly accessible places (parks, shops, streets, or univer-
sity campuses) and private places (participants’ residence). 
Respondents were also required to meet the following inclu-
sion criteria: (1) aged ≥ 18 years; (2) had Chinese nation-
ality; (3) lived in mainland China during the past 5 years; 
(4) were literate and had no disease that limited cognitive 
function, such as dementia; and (5) gave informed consent.
2.4  Data Collection
Data were collected through two-to-one face-to-face com-
puter-assisted personal interviews. The structure of the 
interview was as follows. First, respondents answered quota 
and inclusion criteria questions to confirm they were eligi-
ble for the interview. Second, respondents recorded their 
health state on the SF-6Dv2. Third, respondents completed 
the TTO and  DCETTO tasks in the randomized order. Last, 
respondents provided a series of socio-demographic charac-
teristics. Sound recordings of all interviews were collected 
with the respondents’ permission.
In each of the eight selected cities, interviews were con-
ducted by a local team from a local university. Each team 
was led by a local lead investigator and supervised by the 
principal investigators. A total of 146 interviewers with a 
bachelor’s degree or higher were involved in this study. The 
interviewers attended a 2-day training to ensure equiva-
lent task understanding, procedures, and interactions with 
respondents. Before the beginning of data collection, each 
interviewer was asked to complete three pilot interviews 
under the supervision of both the local lead investigator and 
the principal investigators of this study.
The study protocol was approved by the institutional 
review board of the School of Pharmaceutical Science and 
Technology, Tianjin University (no. 20180615). Informed 
consent was obtained from all respondents included in the 
study.
2.5  Quality Control
The quality of the collected data was monitored daily by the 
principal investigators. Interviews were directly excluded if 
(1) the interview was not completed; (2) respondents were 
not patient enough to follow the interviewers’ guidance; 
or (3) interviewers failed to ask the questions or operate 
the questionnaire system according to the study protocol. 
Potentially problematic data were also identified, includ-
ing respondents who gave the same values for all tasks; 
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gave the worst state (555655) a higher value (at least 0.5) 
than the other states in the TTO exercise [41–44]; always 
selected the same options, such as “AAAAA”; or selected 
“ABABAB” in the  DCETTO [19, 43, 44]. Furthermore, we 
randomly selected 30% of the interview sound recordings for 
further daily double checking by the principal investigators 
to ensure the data quality.
2.6  Data Analysis
TTO data were analyzed according to main-effect specifica-
tion using ordinary least squares (OLS) and Tobit models 
[2, 33]. The basic equation for the OLS model is as shown 
in Equation 1.
where yi represents the disutility value;  represents the 
intercept; x
dl
 represents 25 dummy variables indicating the 
health state described by SF-6Dv2 dimension d at level l , 
except the first level of each dimension (for reference); 
dl
 
represents the estimated disutility on dimension d at level l ; 
and  represents the error term. Considering each respond-
ent completed multiple TTO tasks, in addition to the OLS 
estimator with cluster-robust standard errors, the fixed- and 
random-effects models were also considered to account for 
the panel structure in the data.
The Tobit model has a potentially favorable character-
istic because observed values were left-censored by the 
TTO methodology at − 1, whereas latent preferences of 
respondents might include valuations lower than − 1 for 
health states WTD (Fig. 4 in the ESM). As shown in Eq. (2), 
the Tobit model assumes that a latent variable y∗
i
 underlies 
the observed yi TTO disutility value and uses a likelihood 
function to adjust the parameter estimates for the probability 
of the y∗
i
 value beyond the censored value (i.e., lower than 
− 1). Detailed information for the Tobit model is described 
elsewhere [41, 42, 45].
The  DCETTO data were analyzed under the random util-
ity framework using both a conditional logit model (which 
assumes a homogenous preference from the respondents) 
and a mixed logit model (which allows for potential prefer-
ence heterogeneity among respondents), following the model 
specification proposed by Bansback et al. [19] (Eq. 3).
where Uij represents the binary choice of respondent i for 
 DCETTO task j ; tij represents the life duration, which is 
modeled as a linear, continuous variable;  represents the 

















(3)Uij = tij + λxijtij + ij,
coefficient for the life duration; xijtij represents the interac-
tions between dimension levels and life duration;  repre-
sents the coefficients for the interactions; and ij represents 
the error term, which is assumed to be independently and 
identically distributed with Gumbel distribution. The mixed-
logit model considers preference heterogeneity by estimating 
both the mean (which represents the average preferences of 
respondents) and the standard deviation (SD). In this study, 
a SF-6Dv2 dimension was considered random (with nor-
mal distribution) as long as the SD of at least one response 
level was statistically significant. The  DCETTO value for each 
health state can be anchored on the QALY scale as shown in 
Eq. (4) [19, 26, 27, 29, 30].
2.7  Model Evaluation
The preferred models for both TTO and  DCETTO approaches 
were selected based on (1) the monotonicity of logical order-
ing of the model coefficients, meaning that theoretically, the 
coefficients of more severe levels should have lower values 
than the coefficients of milder levels within each dimension; 
(2) the goodness of fit of the model using Akaike infor-
mation criterion (AIC) and Bayesian information criterion 
(BIC); and (3) the parsimony of the model, meaning that 
the most parsimonious model would be selected if two or 
more models exhibited similar prediction performances. 
Furthermore, for TTO data, the prediction accuracy could 
be assessed by comparing predicted and observed mean val-
ues for health states valued in the study, using the intraclass 
correlation coefficient (ICC), the mean absolute difference 
(MAD), and the mean squared difference (MSD). Lower 
MAD and MSD and higher ICC values indicated better 
accuracy. Several interaction terms were also tested based 
on the preferred model for both TTO and  DCETTO, which 
can be found in Tables 2 and 3 in the ESM. The final model, 
which would be used to calculate the health utility values 
and inform policy, requires the monotonicity of model coef-
ficients [30, 46, 47]. The adjacent inconsistent levels in the 
preferred models were combined in this study to produce a 
fully consistent model.
2.8  Value Set Comparison
Based on the preferred model specification, after handling 
the potential issue of monotonicity, the comparison of the 
characteristics of health utility value sets generated by TTO 
and  DCETTO was evaluated by the descriptive features, 
including the range of the utility value, the utility distribu-
tion of all 18,750 health states in SF-6Dv2, and the number 
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of health states WTD. The consistency between two value 
sets was also evaluated using ICC, MAD, and MSD val-
ues. The degree of agreement between utility values of TTO 
and  DCETTO was assessed using a Bland–Altman plot. The 
cross-validation method was further used to demonstrate 
and compare the robustness of model estimation for both 
approaches. Specifically, data for one of the eight cities were 
excluded and the data for the remaining seven cities used for 
model estimation. This process was repeated eight times, in 
turn excluding data for each of the eight cities. Then, the 
MAD between coefficients of these fitted models and coef-
ficients of the whole sample model was compared.
All statistical analyses were conducted using STATA 
15.1. To compare the distribution of characteristics between 
subgroups, the t test was used for continuous variables and 
the χ2 or Fisher’s exact test was used for categorical varia-
bles. Differences in distribution of characteristics and model 




A total of 3575 respondents were interviewed from June 
to September in 2019 (Fig. 3 in the ESM), of which 255 
interviews were excluded because the respondents did not 
complete the whole interview (N = 174) or the interviews 
did not pass the quality control process (N = 81). Finally, a 
total of 3320 respondents were included, with geographic 
distribution as shown in Fig. 2b in the ESM. As illustrated in 
Table 1, the mean ± SD age of respondents was 44.6 ± 16.1 
years (range 18–90); 50.3% were males, and 40.4% lived in 
rural areas. The characteristics of respondents were close 
to those of the Chinese general population. The distribu-
tions for four quota characteristics were comparable across 
respondents in eight cities, and various distributions were 
observed for other characteristics, reflecting the geographi-
cal spread and different economic development levels in 
China (Table 1 in the ESM).
The mean ± SD time spent in the interview was 39.4 
± 17.0 min, and the duration for TTO tasks was signifi-
cantly longer than for  DCETTO tasks (16.2 vs. 12.9 min; p 
< 0.001). Health problems were most frequently reported 
in the VT dimension (76.7%) and least frequently in PF 
(35.9%) (Fig. 1).
3.2  Data Characteristics
Mean observed TTO values ranged from − 0.243 for state 
555655 to 0.885 for state 111112 and ranged from 0.862 to 
0.885 for the six mildest imperfect health states. Of 26,560 
responses, 5011 (18.9%) were considered WTD. The distri-
bution of observed TTO values for 295 states is presented 
in Fig. 4 in the ESM. For  DCETTO data, as the difference in 
overall severity between the two states increased, respond-
ents were more likely to choose the state with the lower 
severity; as expected, several inconsistencies were found 
because of the additional life duration dimension (Fig. 5 in 
the ESM).
Nevertheless, potentially problematic answer patterns 
were observed, including three respondents who gave the 
same values for all tasks, 51 who gave the worst state a 
higher value (at least 0.5) than the other states in TTO data, 
and respondents who always selected the same options (e.g., 
20 responded “AAAAA” and 19 responded “ABABAB”) in 
the  DCETTO. These respondents were few, with no notice-
able differences in demographic characteristics, and some 
answers may be due to random errors. Therefore, these 
respondents were not excluded from this study.
3.3  Model Estimation
The estimated coefficients of the models on TTO data are 
presented in Table 2. The random-effects model performed 
better as measured by the criteria mentioned and was 
selected for the final data analysis for TTO data. Although 
the mixed logit model performed better in AIC and BIC, 
the conditional logit model was chosen for  DCETTO data 
given that there were fewer non-monotonic coefficients and 
that the preference heterogeneity was not substantial (only 
four dimension levels had statistically significant SDs in 
the mixed logit model) (Table 3). In these two preferred 
models, all of the coefficients for TTO were ordered as 
expected. Level 2 in MH and VT dimensions for  DCETTO 
showed slight non-monotonicity, while the coefficients were 
not statistically significant. The goodness of fit was slightly 
improved after combining the inconsistent levels. Most of 
the coefficients in both TTO and  DCETTO models were sig-
nificantly different from 0 (p < 0.001). All of the interac-
tion terms were excluded in the final models because they 
resulted in non-monotonicity, varying degrees of impairment 
of the model estimations, or the parsimony of the model 
(Tables 2 and 3 in the ESM). 
Following the previous study, the linear adjustment to 
the predicted values of TTO was made using the formula 
UAdjusted = UPredicted/(1 − intercept) (Table 4) [48]. This addi-
tional step was to remove the effect of the non-zero intercept 
in TTO, which leads to a predicted value of less than 1 for 
full health (111111).
3.4  Value Set Comparison
As illustrated in Table 4, values in the two approaches were 
highly consistent (ICC 0.9804, MAD 0.0588, MSD 0.0055). 
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Table 1  Respondent 
characteristics
NA data not included in the publicly available data source, RMB renminbi, SD standard deviation
a Statistics data for the Chinese general population were extracted from the Sixth National Census of China 
[39] and the China Statistical Yearbook [40]
b Quota sampling was used in this study; sex, age, education status, and region were predefined on the basis 
of their distribution in the Chinese general population
c Chronic conditions include hypertension, dyslipidemia, diabetes or high blood sugar, cancer or malignant 
tumor, chronic lung disease, liver disease, heart disease, stroke, kidney disease, stomach or other digestive 
disease, emotional or psychiatric problems, memory-related disease, arthritis or rheumatism, asthma, or 
other respondent-reported chronic conditions
Characteristics Chinese general 
 populationa (%)




 Male 51.2 1670 (50.3) − 0.9
 Female 48.8 1650 (49.7) +0.9
 Age (mean ± SD) NA 44.6 ± 16.1 –
Age group (years)b
 18–29 21.5 708 (21.3) − 0.2
 30–39 18.7 613 (18.5) − 0.2
 40–49 21.1 670 (20.2) − 0.9
 50–59 17.1 614 (18.5) + 1.4
 ≥ 60 21.6 715 (21.5) − 0.1
Educationb
 Primary or lower 26.2 820 (24.7) − 1.5
 Junior high school 40.3 1288 (38.8) − 1.5
 Senior high school 17.2 601 (18.1) + 0.9
 College or higher 16.3 611 (18.4) + 2.1
Regionb
 Urban 59.6 1980 (59.6) − 0.05
 Rural 40.4 1340 (40.4) + 0.05
Marital status
 Unmarried NA 709 (21.4) –
 Married NA 2434 (73.3) –
 Divorced NA 73 (2.2) –
 Widowed NA 104 (3.1) –
Health insurance
 Urban employee NA 1576 (47.5) –
 Urban and rural resident NA 1476 (44.5) –
 Commercial NA 449 (13.5) –
 Other NA 74 (2.2) –
 No NA 188 (5.7) –
Employment status
 Employed NA 2043 (61.5) –
 Retired NA 604 (18.2) –
 Student NA 229 (6.9) –
 Unemployed NA 444 (13.4) –
Monthly income (RMB)
 < 2000 NA 858 (25.8) –
 2000–5000 NA 1831 (55.2) –
 5000–10,000 NA 481 (14.5) –
 > 10,000 NA 150 (4.5) –
Number of chronic  conditionsc
 0 NA 2063 (62.1) –
 1 NA 831 (25.0) –
 2 NA 265 (8.0) –
 3 NA 93 (2.8) –
 ≥ 4 NA 68 (2.0) –
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The orders of overall decrement of the dimensions were the 
same for both approaches, as follows: PN, PF, MH, VT, SF, 
and RL. The Bland–Altman plot (Fig. 6 in the ESM) also 
showed that the mean difference of 0.02 was close to zero, 
the 95% limits of agreement between TTO and  DCETTO 
ranged from − 0.11 to 0.16, and 95.7% of points lay within 
limits. Although agreement was generally good, we also 
observed that TTO values tended to be lower than  DCETTO 
values for milder health states and higher than  DCETTO val-
ues for worse health states. The comparison of the tendency 
of coefficients between TTO and  DCETTO is presented in 
Fig. 2a, which shows that the coefficients of TTO decreased 
more smoothly than  DCETTO. The estimated utility values 
for the 18,750 health states for SF-6Dv2 of both approaches, 
with the benchmark of observed TTO values, are shown in 
Fig. 2b. A similar trend can be found with the Bland–Altman 
plot (Fig. 6 in ESM). In total, 927 (4.94%) health states were 
estimated to be WTD in TTO, which were less than 1593 
(8.50%) in  DCETTO. The utility values of the worst state 
555655 were − 0.277 for TTO and − 0.535 for  DCETTO. 
The cross-validation results showed that excluding the data 
from one of the eight cities had only trivial effects on the 
coefficients for both TTO (less than 0.003) and  DCETTO (less 
than 0.002) (Tables 4 and 5 in the ESM).
The value set generated by the random-effects model of 
TTO data after adjusting the intercept (Table 4) was pre-
ferred over that generated by the conditional logit model 
of  DCETTO data, based on its performance concerning the 
monotonicity and statistical significance of the coefficients. 
In applying this preferred model as the value set of SF-6Dv2 
in China, a health state utility value was obtained by sub-
tracting coefficients for each dimension level of the health 
state from 1. For example, for the health state 232154, the 
utility value would be 1 − (0.038 + 0.059 + 0.047 + 0 + 
0.134 + 0.108) = 0.614.
4  Discussion
This study collected TTO and  DCETTO responses via face-
to-face interviews with 3320 respondents who were repre-
sentative of the general population of China in terms of age, 
sex, education, and proportion of urban/rural population. 
All of these response data were modeled to estimate util-
ity values for all health states in the SF-6Dv2. This study 
presents the first empirical evidence of the systematic differ-
ence between these two approaches that directly compared 
value sets of the SF-6Dv2 generated by TTO and  DCETTO 
approaches. Value sets for the EQ-5D-3L and the EQ-5D-5L 
have already been developed for China [48–50], and this 
study reports a Chinese-specific value set for the SF-6Dv2 
that can be used for economic evaluations. Furthermore, as 
the first to generate a value set for the SF-6Dv2 in Asia, this 
study facilitates cross-country comparisons, which could 
provide further information on the health preference differ-
ences between eastern and western populations.
Both TTO and  DCETTO approaches were feasible for 
eliciting health state utility values, and the orders of over-
all decrement of the dimensions were the same for both 
approaches. There were some (statistically insignificant) 
inconsistent coefficients in the  DCETTO model and, follow-
ing previous literature, the adjacent inconsistent levels were 
combined when developing value sets. It should be noted 
that this issue is not unique to this study and has been found 
in several previous valuation studies using DCE or  DCETTO 
[12, 24, 28–31, 43]. Non-monotonicity of the coefficients 
can be caused by many factors, including respondents’ 
Fig. 1  Distribution across levels 
of the SF-6Dv2 dimensions. 
All dimensions have five levels, 
except for the pain dimension, 
which has six levels; higher 







Table 2  Estimated coefficients (standard errors) of the fitted models on time trade-off data
M1: OLS model M2: RE model M3: FE model M4: Tobit model M5: RE Tobit model
Coef. SE p value Coef. SE p value Coef. SE p value Coef. SE p value Coef. SE p value
Intercept 0.139 0.007 < 0.001 0.130 0.005 < 0.001 0.128 0.007 < 0.001 0.113 0.010 < 0.001 0.105 0.009 < 0.001
Physical functioning
 PF2 0.033 0.008 < 0.001 0.033 0.007 < 0.001 0.033 0.008 < 0.001 0.038 0.010 < 0.001 0.037 0.008 < 0.001
 PF3 0.065 0.010 < 0.001 0.069 0.008 < 0.001 0.070 0.008 < 0.001 0.069 0.010 < 0.001 0.074 0.008 < 0.001
 PF4 0.109 0.010 < 0.001 0.122 0.008 < 0.001 0.125 0.008 < 0.001 0.114 0.010 < 0.001 0.128 0.008 < 0.001
 PF5 0.342 0.011 < 0.001 0.344 0.010 < 0.001 0.344 0.008 < 0.001 0.347 0.010 < 0.001 0.348 0.008 < 0.001
Role limitation
 RL2 0.041 0.009 < 0.001 0.044 0.007 < 0.001 0.044 0.008 < 0.001 0.045 0.010 < 0.001 0.047 0.008 < 0.001
 RL3 0.053 0.011 < 0.001 0.052 0.009 < 0.001 0.051 0.009 < 0.001 0.058 0.011 < 0.001 0.056 0.009 < 0.001
 RL4 0.087 0.009 < 0.001 0.083 0.008 < 0.001 0.083 0.008 < 0.001 0.092 0.010 < 0.001 0.087 0.008 < 0.001
 RL5 0.089 0.010 < 0.001 0.084 0.008 < 0.001 0.083 0.008 < 0.001 0.093 0.010 < 0.001 0.088 0.008 < 0.001
Social functioning
 SF2 0.040 0.009 < 0.001 0.041 0.008 < 0.001 0.041 0.008 < 0.001 0.044 0.010 < 0.001 0.045 0.008 < 0.001
 SF3 0.053 0.010 < 0.001 0.052 0.008 < 0.001 0.052 0.008 < 0.001 0.057 0.010 < 0.001 0.056 0.008 < 0.001
 SF4 0.079 0.010 < 0.001 0.081 0.008 < 0.001 0.082 0.008 < 0.001 0.084 0.010 < 0.001 0.086 0.008 < 0.001
 SF5 0.090 0.010 < 0.001 0.094 0.008 < 0.001 0.095 0.008 < 0.001 0.094 0.010 < 0.001 0.098 0.008 < 0.001
Pain
 PN2 0.041 0.009 < 0.001 0.041 0.008 < 0.001 0.041 0.008 < 0.001 0.048 0.010 < 0.001 0.047 0.008 < 0.001
 PN3 0.067 0.011 < 0.001 0.072 0.009 < 0.001 0.073 0.009 < 0.001 0.073 0.012 < 0.001 0.078 0.009 < 0.001
 PN4 0.127 0.011 < 0.001 0.134 0.009 < 0.001 0.136 0.009 < 0.001 0.135 0.011 < 0.001 0.141 0.009 < 0.001
 PN5 0.330 0.012 < 0.001 0.338 0.010 < 0.001 0.339 0.009 < 0.001 0.338 0.011 < 0.001 0.346 0.009 < 0.001
 PN6 0.369 0.012 < 0.001 0.372 0.010 < 0.001 0.372 0.009 < 0.001 0.376 0.011 < 0.001 0.378 0.009 < 0.001
Mental health
 MH2 0.020 0.009 0.035 0.028 0.008 < 0.001 0.030 0.008 < 0.001 0.023 0.010 0.022 0.032 0.008 < 0.001
 MH3 0.052 0.011 < 0.001 0.043 0.009 < 0.001 0.041 0.008 < 0.001 0.058 0.010 < 0.001 0.048 0.008 < 0.001
 MH4 0.119 0.011 < 0.001 0.115 0.008 < 0.001 0.115 0.008 < 0.001 0.125 0.010 < 0.001 0.124 0.008 < 0.001
 MH5 0.120 0.010 < 0.001 0.116 0.008 < 0.001 0.114 0.008 < 0.001 0.127 0.010 < 0.001 0.123 0.008 < 0.001
Vitality
 VT2 0.017 0.009 0.049 0.025 0.007 < 0.001 0.027 0.008 0.001 0.019 0.010 0.054 0.027 0.008 0.001
 VT3 0.053 0.011 < 0.001 0.053 0.008 < 0.001 0.053 0.008 < 0.001 0.056 0.010 < 0.001 0.056 0.008 < 0.001
 VT4 0.090 0.011 < 0.001 0.094 0.008 < 0.001 0.095 0.009 < 0.001 0.094 0.011 < 0.001 0.097 0.009 < 0.001
 VT5 0.093 0.010 < 0.001 0.101 0.008 < 0.001 0.103 0.008 < 0.001 0.096 0.010 < 0.001 0.104 0.008 < 0.001
Breusch Pagan LM test < 0.001 (RE model was preferred) – –
Hausman test 0.409 (RE model was preferred) – –
Log likelihood − 18813.96 − 14711.84 − 9739.92 − 19169.09 − 15101.28
AIC 37679.92 29479.69 19531.84 38392.18 30258.57
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characteristics, instruments used to describe health states, 
health states selected for valuation, and the model chosen to 
estimate the data. It has also been reported in studies con-
ducted in different countries, among respondents with differ-
ent characteristics and cultural backgrounds [12, 24, 28, 31, 
43]; using different instruments [12, 24, 29, 30]; estimating 
data based on different models [12, 29, 30]; or even using 
different health states [12, 31]. Further research exploring 
the issue of inconsistent coefficients in DCE approaches is 
encouraged.
Although the value set generated by TTO data was 
favored over that generated by  DCETTO data given the 
monotonicity and statistical significance of the coefficients, 
 DCETTO did generate sensible results. The utility values 
generated by  DCETTO were generally lower than those pro-
vided by TTO, which is consistent with previous studies 
[19, 26]. When compared with the UK value set for the 
SF-6Dv2, the range of values was similar, despite the dif-
ferent health states and experimental designs used for the 
 DCETTO approach [12]. Specifically, the range of values was 
from 1 (111111) to − 0.535 (555655) for China and from 
1 (111111) to − 0.574 (555655) for the UK, with the UK 
value set producing a slightly lower value [12]. The number 
of health states WTD was 1593 (8.50%) for China and 2850 
(15.2%) for the UK [12]. The PN dimension had the larg-
est decrement, and RL had the smallest, for both the China 
and the UK value sets; nevertheless, the order of the other 
dimensions was not identical. Further studies are warranted 
to compare the TTO and  DCETTO value sets to provide more 
evidence when using  DCETTO as a promising alternative to 
TTO, based on previous discussions [19, 31].
The value set generated by the TTO data was preferred 
in this study, even though statistically significant non-zero 
intercepts were observed. This was mainly because respond-
ents gave low values for the very mild health state. This 
finding also existed in the Chinese EQ-5D-5L valuation 
study, which had an intercept of 0.121 [48]. Therefore, this 
issue may be related to the health preferences of the Chi-
nese population, which tend to give very mild states a lower 
value. A significant intercept would favor and could result 
in overinvestment in treatments for very mild health prob-
lems. Therefore, following the Chinese EQ-5D-5L valuation 
study [48], a linear adjustment to all model coefficients was 
applied in this study in terms of using the SF-6Dv2 value set 
to better inform healthcare decision making.
This study also found that the decrement of the PN and 
the PF dimensions were the largest, indicating that the 
Chinese general population gave more weight to these two 
dimensions than other dimensions in SF-6Dv2. This is con-
sistent with SF-6Dv1 value sets for Hong Kong China and 
Japan, which had the largest decrement for the same two 
dimensions [51, 52]. Similarly, in both Chinese EQ-5D-3L 































































































































































































































































































































































































































































































































Table 3  Estimated coefficients (standard errors) of the fitted models on  DCETTO data
Conditional logit model (after 
combination)
Mixed logit model Conditional logit model (after 
combination)
Conditional logit model 
Anchored utility
Coef. SE p value Coef. SE p value SD SE p value Coef. SE p value Coef. 95% CI
Year 0.365 0.009 < 0.001 0.465 0.013 <0.001 0.247 0.006 < 0.001 0.370 0.008 < 0.001 – –
Physical functioning × year
 PF2 − 0.009 0.005 0.052 − 0.008 0.006 0.168 0.068 0.012 0.060 − 0.010 0.005 0.043 − 0.027 − 0.0011 to − 0.0520
 PF3 − 0.018 0.005 < 0.001 − 0.022 0.006 < 0.001 0.046 0.013 0.075 − 0.019 0.004 < 0.001 − 0.050 − 0.0267 to − 0.0736
 PF4 − 0.054 0.005 < 0.001 − 0.069 0.005 < 0.001 0.005 0.020 0.791 − 0.054 0.005 < 0.001 − 0.145 − 0.1206 to − 0.1688
 PF5 − 0.150 0.005 < 0.001 − 0.217 0.007 < 0.001 0.171 0.009 < 0.001 − 0.150 0.005 < 0.001 − 0.404 − 0.3774 to − 0.4308
Role limitation × year
 RL2 − 0.011 0.004 0.010 0.001 0.006 0.965 0.006 0.020 0.760 − 0.011 0.004 0.010 − 0.029 − 0.0073 to − 0.0516
 RL3 − 0.011 0.005 0.017 − 0.023 0.006 < 0.001 0.066 0.011 0.078 − 0.011 0.005 0.018 − 0.030 − 0.0056 to − 0.0552
 RL4 − 0.030 0.004 < 0.001 − 0.024 0.006 < 0.001 0.043 0.016 0.006 − 0.030 0.004 < 0.001 − 0.081 − 0.0589 to − 0.1034
 RL5 − 0.041 0.005 < 0.001 − 0.009 0.006 0.137 0.005 0.058 0.926 − 0.041 0.005 < 0.001 − 0.112 − 0.0880 to − 0.1354
Social functioning × year
 SF2 − 0.013 0.005 0.004 − 0.010 0.006 0.071 – – – − 0.013 0.005 0.004 − 0.035 − 0.0114 to − 0.0586
 SF3 − 0.014 0.004 0.001 − 0.027 0.006 < 0.001 – – – − 0.014 0.004 0.001 − 0.038 − 0.0151 to − 0.0613
 SF4 − 0.039 0.004 < 0.001 − 0.051 0.006 < 0.001 – – – − 0.039 0.004 < 0.001 − 0.104 − 0.0819 to − 0.1266
 SF5 − 0.042 0.004 < 0.001 − 0.048 0.006 < 0.001 – – – − 0.042 0.004 < 0.001 − 0.114 − 0.0923 to − 0.1348
Pain × year
 PN2 − 0.027 0.005 < 0.001 − 0.032 0.006 < 0.001 0.037 0.014 0.068 − 0.027 0.005 < 0.001 − 0.072 − 0.0446 to − 0.0996
 PN3 − 0.029 0.005 < 0.001 − 0.013 0.007 0.054 0.058 0.014 0.213 − 0.029 0.005 < 0.001 − 0.079 − 0.0536 to − 0.1054
 PN4 − 0.057 0.005 < 0.001 − 0.061 0.007 < 0.001 0.032 0.014 0.020 − 0.057 0.005 < 0.001 − 0.155 − 0.1295 to − 0.1802
 PN5 − 0.173 0.006 < 0.001 − 0.216 0.007 < 0.001 0.078 0.012 0.093 − 0.173 0.006 < 0.001 − 0.466 − 0.4382 to − 0.4948
 PN6 − 0.200 0.005 < 0.001 − 0.263 0.007 < 0.001 0.127 0.011 < 0.001 − 0.200 0.005 < 0.001 − 0.541 − 0.5126 to − 0.5688
Mental health × year
 MH2 0.002 0.004 0.686 0.004 0.006 0.543 – – – 0.000 – – 0.000 –
 MH3 − 0.003 0.004 0.568 − 0.026 0.006 < 0.001 – – – − 0.004 0.004 0.341 − 0.010 0.0104 to − 0.0303
 MH4 − 0.053 0.005 < 0.001 − 0.075 0.006 < 0.001 – – – − 0.054 0.004 < 0.001 − 0.146 − 0.1266 to − 0.1656
 MH5 − 0.072 0.005 < 0.001 − 0.099 0.006 < 0.001 – – – − 0.073 0.004 < 0.001 − 0.197 − 0.1750 to − 0.2193
Vitality × year
 VT2 0.007 0.005 0.145 0.019 0.006 0.001 – – – 0.000 – – 0.000 –
 VT3 − 0.027 0.005 < 0.001 − 0.011 0.006 0.058 – – – − 0.031 0.004 < 0.001 − 0.083 − 0.0611 to − 0.1040
 VT4 − 0.029 0.005 < 0.001 − 0.044 0.006 < 0.001 – – – − 0.033 0.004 < 0.001 − 0.089 − 0.0702 to − 0.1085
 VT5 − 0.058 0.005 < 0.001 − 0.070 0.006 < 0.001 – – – − 0.062 0.004 < 0.001 − 0.167 − 0.1475 to − 0.1871











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 4  Comparison between health utility value sets generated by time 
trade-off and discrete-choice experiments with a duration dimension
The value set generated by TTO was based on model 2 (random-effects 
model) shown in Table  2, and the linear adjustment to remove the 
effect of the non-zero intercept was made using the formula UAdjusted = 
UPredicted/(1 − intercept). The value set generated by  DCETTO was based 
on the anchored coefficients of the conditional logit model (Table  3) 
with the combination of inconsistent coefficients
Coef. coefficient, DCETTO discrete-choice experiments with a dura-
tion dimension, ICC intraclass correlation coefficient, MAD mean 
absolute difference, MH mental health, MSD mean squared differ-
ence, PF physical functioning, PN pain, RL role limitation, SF social 





 PF2 − 0.038 − 0.027
 PF3 − 0.080 − 0.050
 PF4 − 0.140 − 0.145
 PF5 − 0.395 − 0.404
Role limitation
 RL1 0.000 0.000
 RL2 − 0.050 − 0.029
 RL3 − 0.059 − 0.030
 RL4 − 0.096 − 0.081
 RL5 − 0.097 − 0.112
Social functioning
 SF1 0.000 0.000
 SF2 − 0.047 − 0.035
 SF3 − 0.060 − 0.038
 SF4 − 0.093 − 0.104
 SF5 − 0.108 − 0.114
Pain
 PN1 0.000 0.000
 PN2 − 0.047 − 0.072
 PN3 − 0.083 − 0.079
 PN4 − 0.154 − 0.155
 PN5 − 0.388 − 0.466
 PN6 − 0.427 − 0.541
Mental health
 MH1 0.000 0.000
 MH2 − 0.033 0.000
 MH3 − 0.050 − 0.010
 MH4 − 0.132 − 0.146
 MH5 − 0.134 − 0.197
Vitality
 VT1 0.000 0.000
 VT2 − 0.029 0.000
 VT3 − 0.060 − 0.083
 VT4 − 0.108 − 0.089
 VT5 − 0.116 − 0.167
No. (%) of worse than death 927 (4.94%) 1593 (8.50%)
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discomfort and mobility dimensions was the largest [48, 
50] similar to the EQ-5D-5L value sets for South Korea, 
Malaysia, and Thailand [53–55]. However, in the Chinese 
EQ-5D-3L (2018) value set [49], the decrement for the 
self-care dimension was the largest, and pain/discomfort 
was the smallest, which differed from these studies. This 
inconsistency may be partly because of the different TTO 
task design used to generate the Chinese EQ-5D-3L (2018) 
value set [49]. In western countries, such as the USA, the 
UK, Germany, and the Netherlands, the decrements in the 
PN and MH dimensions in the SF-6Dv1 [56, 57] and in the 
pain/discomfort and anxiety/depression dimensions in the 
EQ-5D-5L [41, 45, 58], were the largest. Although different 
measures were used in these studies, the similarities in the 
health state classification system provided good comparabil-
ity. Populations of both eastern and western countries may 
give similarly large preferences for PN. In contrast, popu-
lations of eastern countries may give more weight to PF, 
while those of western countries may have more preference 
for MH. The similarities and distinctions in the ranking of 
the dimensions reflect cultural and socioeconomic factors, 
which are essential to shaping the preferences of popula-
tions. Further investigation is needed to explore and compare 
the impact on the results of economic evaluations by using 
the newly established SF-6Dv2 value set in this study and 
the existing Chinese EQ-5D value sets as mentioned.
Fig. 2  Comparison of the value sets generated by TTO and  DCETTO. 
a Comparison of the tendency of coefficients between TTO and 
 DCETTO. b Estimated utility values for the 18,750 health states for the 
SF-6Dv2 based on the TTO and  DCETTO data, with the benchmark 
of observed TTO values (ordered by the TTO observed values). TTO 
time trade-off, DCETTO discrete-choice experiment with a duration 
dimension
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A particular strength of this study is its sample size, 
which was larger than most of the other valuation studies 
[59–62] and helped to reduce the standard errors of model 
coefficients (no larger than 0.01 in this study). Besides, given 
the large proportion of rural residents in China, an impor-
tant factor that may affect health preferences [49, 63, 64], a 
specific quota of the urban and rural proportion of the Chi-
nese general population was employed for the first time in 
this study. This improved the representativeness of the study 
sample and provided a more reliable health utility value set 
to reflect the health preferences of the Chinese population.
Several limitations of this study need to be noted. First, 
146 interviewers involved in this study had the same exten-
sive training but came from different backgrounds and used 
different communication skills when conducting the inter-
views. Although the cross-validation results showed that 
excluding the data from one of the eight cities had only 
trivial effects on the model estimation, there may be some 
unobservable effects [65]. Second, to achieve the maximum 
statistical efficiency of modeling, implausible health states 
in SF-6Dv2 were not excluded in the experimental design 
for both TTO and  DCETTO. Asking respondents to consider 
implausible health states was likely to have had an impact 
on the quality of their responses and may have affected the 
model estimation results. There was also a lack of agreement 
among respondents on which states were implausible [66]. 
Furthermore, the order of the eight tasks in each TTO block 
was not completely random. The mildest state and the worst 
state were always the seventh and eighth states, respectively, 
because of the technical limitations during production of 
the survey. This could have had some minor impacts on the 
estimates.
5  Conclusions
The Chinese value set for the SF-6Dv2 was established 
based on the TTO approach, and both TTO and  DCETTO 
approaches performed well when eliciting health state util-
ity values in China. Minor issues of non monotonicity did 
present for  DCETTO.
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